General side effects: tiredness, headache, muscle pain, chills, joint pain, fever, nausea, feeling unwell, swollen lymph ...

Notable medicines subject to price increases include Pfizer’s COVID-19 drug Paxlovid, Bristol Myers Squibb’s CAR-T therapies Abecma and Breyanzi and a clutch of vaccines from Sanofi ...

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the cash-strapped biotech of up to $220 million in milestones. Pfizer’s decision sent ...

Sangamo Therapeutics (NASDAQ:SGMO) lost nearly half of its market cap in early trading on Tuesday after Pfizer (NYSE:PFE) decided to end a collaboration with the company for its gene therapy ...

Pfizer Inc. defeated a lawsuit from Texas Attorney General Ken Paxton that alleged the pharmaceutical giant misrepresented the effectiveness of its Covid-19 vaccine. Pfizer is entitled to immunity ...

Dec 30 (Reuters) - Sangamo Therapeutics (SGMO.O), opens new tab said on Monday that partner Pfizer (PFE.N), opens new tab has terminated their hemophilia A gene therapy co-development agreement ...

Holmes will also have to answer about how a Pfizer logo appeared on an internally produced document. Undoubtedly, these issues will be raised by the prosecution during cross-examination if the defense ...

VectSharp is a library to create vector graphics (including text) in C#, without too many dependencies. VectSharp is written using .NET Core, and is available for Mac, Windows and Linux. Since version ...

They even generated clinical results that suggested it might have promise as a weight-loss drug as well — only to have Pfizer, which had agreed to fund the research, withdraw its support ...

Pfizer's stock has underperformed, but management's focus on R&D and cost efficiencies should boost margins and free cash flow, supporting a Buy rating. Despite political headwinds, PFE's ...

Pfizer reiterated its forecast for 2024 and issued a new one for 2025. Management generally tried to calm some worries from rattled shareholders. There are still a couple of issues to be aware of ...

Pfizer has been reining in costs and shedding non-core businesses to pay down debt as it rebuilds itself after a sharp slump in sales of COVID-19 products. Its shares have fallen nearly 12 per ...